Biotechnology stocks have traded basically sideways since the start of 2023. In the face of higher rates, stronger US dollar, inflation, FDA approvals and busts, and an emerging...
July's CPI report may show a 3.3% increase, up from June's 3.0% reading. I believe inflation will likely rise in the coming months due to higher energy and food costs. So, I used...
Earnings season continues, with healthcare companies set to report next week Among them is Pfizer, whose stock has corrected significantly of late Based on the company's strong...
Biotech stocks may be one of the big winners if the Federal Reserve is almost finished raising interest rates. CRISPR Therapeutics is at the forefront of gene editing, which may be...
Stagflation remains one of the primary risks for the global economy in 2023. The stock market’s trajectory will continue to be dictated by worries over persistently high...
The stock market appears to have spent the vast majority of the last week or so doing, well, a lot of nothing. In short, the S&P 500 has moved up into the high end of the recent...
The pharmaceutical industry is a top investment option, with the sector experiencing rapid growth in recent years. The COVID-19 pandemic has also shifted the market focus to the...
Solid earnings lift US stocks to multi-month highs despite hawkish Fed soundbitesYen slips further as markets unrattled by China flexing its military muscle over TaiwanPound edges...
S&P 500 EPS growth for Q2 is set to come in at 6.0%, the lowest level since Q4 2020 Some highly anticipated names reported last week, with big EPS misses from big...
Stocks surged in July, with the major indexes enjoying their best gains since 2020. But the market is still off substantially for the year. The rally came despite the Federal...
Who cares about dividends when this stock shows weakness year after year, is not a good deal to get 5% per year if you are constantly worried about this stock sinks under 2013 lows
invest stock gild.us at basel markets to take home divedends
0
Projected earnings beat but I'd bet it doesn't move the needle -
0
Another 15 or so shares into this.
1
I've held this since 2014 or so. COULD have picked NVDA for approx 15 - 20 😒Did I pick the winner eh?
2
Amazing how GILD managed to disappoint on EVERY earnings report.
4
Yes, even a beat is disapointing -
0
What's happening?!
1
Everyone in market is here to make money. Gilead saved my wife's life. I will donate all my money for this one organization who is working to safe our life ...